In clinical investigations and practice, mexiletine has been shown to be more effective for gene-specific therapy for patients with long-QT syndrome type 3 (LQT3) caused by SCN5A gain-of-function mutations that dramatically affect Nav1.5 channel gating [9, 10]. The gene discussed is SCN5A; the disease is long QT syndrome 3.